Novartis BTK inhibitor shows efficacy in multiple sclerosis trial

Novartis reported positive results for its BTK inhibitor in multiple sclerosis, a potential new treatment option. The win could reshape the MS treatment landscape, though regulatory approval and long-term safety data remain pending. This development is significant for the biotech sector and patients, but its market impact is sector-specific.